PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

Intralesional therapy with oncolytic viruses (OVs) leads to the activation of local and systemic immune pathways, which may present targets for further combinatorial therapies. Here, we used human tumor histocultures as well as syngeneic tumor models treated with Newcastle disease virus (NDV) to ide...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Journal of clinical investigation Ročník 128; číslo 4; s. 1413 - 1428
Hlavní autoři:	Zamarin, Dmitriy, Ricca, Jacob M., Sadekova, Svetlana, Oseledchyk, Anton, Yu, Ying, Blumenschein, Wendy M., Wong, Jerelyn, Gigoux, Mathieu, Merghoub, Taha, Wolchok, Jedd D.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States American Society for Clinical Investigation 01.04.2018
Témata:	Analysis Apoptosis Biomedical research Cancer therapies Care and treatment Cell death Clinical trials Drug therapy Genes Health aspects Immunotherapy Infections Interferon Ligands Lymphocytes Lymphocytes T Melanoma Metastases Metastasis Newcastle disease Oncolysis Patient outcomes PD-1 protein PD-L1 protein Skin cancer Therapeutic targets Tumors Viruses United States Oncology Immunology Gene therapy T cells Immunotherapy
ISSN:	0021-9738, 1558-8238, 1558-8238
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!